Carvykti took nearly 4 years from its first clinical trial approval to its final launch, and preclinical research also took significant time and effort. The efficacy and safety evaluation of preclinical drugs is crucial for investigational new drug (IND) application. This article will introduce the selection of pharmacological models centering on preclinical studies of CAR T-cell therapy.
Read More ›
Genes play a highly significant role in the pathogenesis of eye diseases, some of which are highly prevalent in children and adults. Over 60% of cases of childhood blindness are caused by genetic factors (congenital glaucoma, ocular malformations, atrophy of the optic nerve, and retinitis pigmentosa). In adults, genetic factors can also be associated with serious eye diseases, including glaucoma and macular degeneration.
Read More ›
Cyagen assists in the research of rare diseases and provides various mouse/rat models, including the SYNGAP1-related rodent animal models. This article focuses on the gene SYNGAP1 and rare disease MRD5, aiming to help interested researchers continue to build on scientific literature and knowledge.
Read More ›
Cyagen is proud to announce the availability of BALB/c mouse models for all embryonic stem cell (ESC) based gene targeting services, including our proprietary TurboKnockout® technology.
Read More ›
With the rapid advancement of biomedical technology in recent years, customized treatment methods such as targeted medicine, immunotherapy, and gene therapy have become the main directions of biomedical innovation - which is intimately related to the development of gene-editing technology.
Read More ›
Subscribe Now
Keep receiving FREE resources about research trends and promotional offers.
We use cookies to ensure that we give you the best experience on our website. To learn about how we
keep your information safe, view our Privacy Policy.
OKPrivacy policy
